{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:12:59Z","timestamp":1790097179976,"version":"4.0.1"},"reference-count":52,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["OncoImmunology"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/2162402x.2026.2736333","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:58:15Z","timestamp":1790096295000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapy"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3386-8224","authenticated-orcid":false,"given":"Corey Keith","family":"Goldman","sequence":"first","affiliation":[{"name":"NYU Langone Health\/MedAlliance Medical Health Services","place":["New York, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.04.003"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.01.004"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.09.024"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb00035.x"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.1.14"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00429-6"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M705725200"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071913"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2449"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.5.771"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020772"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.028"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425274"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2399"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1911678117"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1405514111"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0945"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0093-T"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600240103"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901244"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2011.09.028"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200167"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1231"},{"key":"e_1_3_8_27_1","unstructured":"U.S. Food and Drug Administration . FDA approves nogapendekin alfa inbakicept-pmln with BCG for BCG-unresponsive non-muscle invasive bladder cancer. Published April 22 2024. Accessed April 12 2026. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer."},{"key":"e_1_3_8_28_1","unstructured":"U.S. Food and Drug Administration . ANKTIVA (nogapendekin alfa inbakicept-pmln) injection prescribing information. Revised April 2024 Accessed July 30 2026. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761336s000lbl.pdf."},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30148-7"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01669-3"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3470"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100057"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80566-X"},{"key":"e_1_3_8_34_1","unstructured":"U.S. Food and Drug Administration . Proleukin (aldesleukin) injection label. Accessed April 12 2026. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103293s5130lbl.pdf."},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00295-9"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001"},{"issue":"3","key":"e_1_3_8_37_1","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins MB","year":"1997","unstructured":"Atkins MB , Robertson MJ , Gordon M , Lotze MT , DeCoste M , DuBois JS , Ritz J , Sandler AB , Edington HD , Garzone PD , et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997;3(3):409\u2013417.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_8_38_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813192106"},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-419283"},{"key":"e_1_3_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.01.006"},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80013-8"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2011.04.006"},{"key":"e_1_3_8_43_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96219"},{"key":"e_1_3_8_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1202870109"},{"key":"e_1_3_8_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1912885"},{"key":"e_1_3_8_46_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096705"},{"key":"e_1_3_8_47_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201964"},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407"},{"key":"e_1_3_8_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1040-4"},{"key":"e_1_3_8_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02689"},{"key":"e_1_3_8_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2451"},{"key":"e_1_3_8_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-006700"},{"key":"e_1_3_8_53_1","unstructured":"ClinicalTrials.gov . QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Previously Received Treatment With Immune Checkpoint Inhibitors. NCT03228667. Accessed August 5 2026. 2026. https:\/\/clinicaltrials.gov\/study\/NCT03228667."}],"container-title":["OncoImmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/2162402X.2026.2736333","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/2162402X.2026.2736333","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/2162402X.2026.2736333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:58:18Z","timestamp":1790096298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2162402X.2026.2736333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/2162402X.2026.2736333"],"URL":"https:\/\/doi.org\/10.1080\/2162402x.2026.2736333","relation":{},"ISSN":["2162-402X"],"issn-type":[{"value":"2162-402X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=koni20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=koni20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2736333"}}